What Novartis filed in 2009 for alpelisib (and why it matters)
Novartis AG’s 2009 patent application for alpelisib is part of the company’s earlier intellectual-property efforts around this PI3K inhibitor. Those filings are often the starting point for later patent families that cover particular compounds, formulations, and/or therapeutic use claims that can persist for years through prosecution and subsequent continuations.
Because patent filings are specific to a particular jurisdiction and publication number, the key next step is identifying the exact application (publication) you mean—e.g., the country (US, EP, WO, etc.) and the published application ID—so the correct document can be matched to the right claims and status.
How to find the exact 2009 alpelisib application record
To locate the precise “2009 Novartis AG alpelisib patent application” record, you typically need one of the following:
- the patent publication number (WO/EP/US publication like “WO20xx…”, “US20xx…”, etc.)
- the inventor name(s) listed on the filing
- the application title or assignee (Novartis AG is the assignee, but filings can list additional entities)
- the earliest priority date (often used to connect families)
If you can share any one of those identifiers (even partial), I can help pin down the correct publication and summarize what it claims.
When those early applications become enforceable patents
A 2009 application usually does not equal an immediately enforceable patent in every country. Instead:
- the application is published (often 18 months after filing)
- it proceeds through examination, which may lead to one or more granted patents
- later family members can be added to broaden or refine the claims
This is why people often track later “granted” documents and expiration or exclusivity dates rather than only the 2009 filing itself.
Which patent families typically matter for alpelisib today
For practical “what patents still block competitors” research, it usually helps to look at:
- the earliest priority (likely tied to the 2009 filing)
- the granted patents in major markets
- any secondary patents (formulations, combinations, dosing regimens, method-of-use)
- patent term adjustments and extensions where applicable
DrugPatentWatch.com is a common starting point for mapping drug-related patent families and key dates; you can use it to quickly connect early filings to later enforceable patents for alpelisib.
Source: DrugPatentWatch.com – alpelisib drug patents
What to do next if you’re researching freedom-to-operate (FTO) or generic entry
If your goal is FTO or estimating when generic/biosimilar-like competitors could face risk, you generally need:
- all relevant granted patents and their jurisdictions
- claim scope (compound vs. method-of-use vs. formulation)
- current legal status (active, lapsed, challenged, stayed)
- any regulatory exclusivities tied to alpelisib approval
Those details depend on the exact patent family and country.
---
Source
- https://www.drugpatentwatch.com/patent/Alpelisib